ABSTRACT
Background: Radiotherapy is one of the primary modalities of cancer treatment but may associated with short and long-term toxicities. Oral mucositis is frequently encountered in head and neck cancer resulting in unplanned treatment breaks. Few studies emphasized that use of oral glutamine may significantly reduce oral mucositis and other acute toxicities. This study aims to assess the effects of glutamine on oral mucositis in head and neck cancer patients receiving chemo-radiation.Methods: It is a prospective study carried out in sixty-four head and neck cancer patients attending radiotherapy department for chemo-radiation from January 2018 to May 2019. Patients were randomly assigned into two arms containing 32 subjects in each. All the patients in arm-A were taking oral glutamine supplement of 15 mg once daily, two hours prior to radiation and arm-B serve as the control group. Dose of radiation fixed at 66 Gy in 33 fractions over a period of 7 weeks along with an infusion of weekly cisplatin (40 mg/m2). Patients were evaluated regarding onset, severity and the recovery period of mucositis.Results: Oral mucositis appeared at around 5th week in arm-A and 3rd week in arm-B (p<0.0001). Number of patients with mucositis is significantly less in arm-A (75%, 24 out of 32) as compared to arm-B (96.8%) (p=0.0310). The time required for healing of mucositis is significantly less than 1 week in arm-A compared to ~2 weeks in the arm-B (p<0.0001).Conclusions: Oral glutamine when given prior to radiation results in delayed onset of oral mucositis with decreased severity and an early healing period.
ABSTRACT
Introduction: Radiation-induced mucositis is quite bothersome due to acute complications in patients receiving radiotherapy(RT) and even more pronounced with the combined chemoradiotherapy. Mucositis manifests itself as erythema, edema, orulceration that can be accompanied by a mild burning sensation.Aim: This study aims to compare the efficacy of oral glutamine in the prevention of chemoradiotherapy-induced oral mucositisin head-and-neck cancer patients.Materials and Methods: A total of 40 patients with malignancy confirmed in histopathology who were undergoing conventionalRT for head-and-neck cancer were divided into two groups, Group A receives oral glutamine 10 g in 1000 ml of water 2 h beforethe RT and Group B undergoes conventional RT. The outcome was measured in the 6th week of RT and 3rd week of post-RT.Results: Twenty-six patients (65%) had carcinoma of the oropharynx, while 14 patients (35%) had carcinoma of the larynx.In this study, 75% of patients in Group A and 85% of patients in Group B are in Stage IV cancers. Supplementation with oralglutamine before RT shown a significant reduction in incidence of mucositis compared to the control group. Post-RT, there wasa significant reduction in number mucositis cases in Group A than Group B.Conclusion: Oral glutamine decreased the incidence of chemoradiotherapy-induced oral mucositis.